UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 | Regulation FD Disclosure. |
Kura Oncology, Inc. (“Kura”) is aware of media reports indicating a possible liquidity concern at Silicon Valley Bank (“SVB”). Kura considers its exposure to any liquidity concern at SVB as immaterial.
The information in this Item 7.01 is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KURA ONCOLOGY, INC. | ||||||
Date: March 10, 2023 | By: | /s/ Teresa Bair | ||||
Teresa Bair | ||||||
Chief Legal Officer |
Document and Entity Information |
Mar. 10, 2023 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001422143 |
Document Type | 8-K |
Document Period End Date | Mar. 10, 2023 |
Entity Registrant Name | KURA ONCOLOGY, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-37620 |
Entity Tax Identification Number | 61-1547851 |
Entity Address, Address Line One | 12730 High Bluff Drive |
Entity Address, Address Line Two | Suite 400 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | (858) |
Local Phone Number | 500-8800 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.0001 per share |
Trading Symbol | KURA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
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